Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
about
The effect of chitooligosaccharides on oleic acid-induced lipid accumulation in HepG2 cellsMetformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Comparison of Pioglitazone and Metformin Efficacy against Glucocorticoid Induced Atherosclerosis and Hepatic Steatosis in Insulin Resistant Rats.Lactate-Induced Glucose Output Is Unchanged by Metformin at a Therapeutic Concentration - A Mass Spectrometry Imaging Study of the Perfused Rat Liver.Metformin attenuates triglyceride accumulation in HepG2 cells through decreasing stearyl-coenzyme A desaturase 1 expression.
P2860
Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metformin in the treatment of ...... afety, efficacy and mechanism.
@en
type
label
Metformin in the treatment of ...... afety, efficacy and mechanism.
@en
prefLabel
Metformin in the treatment of ...... afety, efficacy and mechanism.
@en
P2093
P2860
P1476
Metformin in the treatment of ...... afety, efficacy and mechanism.
@en
P2093
Ludovico Abenavoli
Natasa Milic
Samir Rouabhia
P2860
P304
P356
10.1586/17474124.2014.894880
P577
2014-03-03T00:00:00Z